New concepts of cytokines in asthma: Is the Th2/Th1 paradigm out the window?
SL Prescott,
SL Prescott
School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia
Search for more papers by this authorSL Prescott,
SL Prescott
School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia
Search for more papers by this authorAssociate Professor SL Prescott, PO Box D184, Princess Margaret Hospital, Perth, WA 6001, Australia. Fax: +61 8 9388 2097; email: [email protected]
Abstract
Abstract: Although asthma is clearly associated with a systemic propensity for allergic T helper type 2 (Th2) cell cytokine responses, independent local immune events appear to be responsible for the development of allergic airways inflammation. There is growing interest in how local immune networks interact with resident airway cell populations such as epithelial cells, which are now also recognized as key producers of cytokines, chemokines and growth factors. As well as their recognized role in airway remodelling, epithelial cells are now thought to have a role in initiating events. This review examines the role of cytokines produced by these and other cells in the development of asthma. It also highlights emerging concepts that the excessive and inappropriate immune responses seen in allergic disease may be related to dysfunction of various interleukin-10 producing regulatory cell populations.
References
- 1 Azzawi M, Bradley B, Jeffery PK et al. Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. Am. Rev. Respir. Dis. 1990; 142: 1407−13.
- 2 Robinson D, Hamid Q, Bentley A, Ying S, Kay AB, Durham SR. Activation of CD4+ T cells, increased TH2-type cytokine mRNA expression, and eosinophil recruitment in bronchoalveolar lavage after allergen inhalation challenge in patients with atopic asthma. J. Allergy Clin. Immunol. 1993; 92: 313−24.
- 3 Ng TW, Holt PG, Prescott SL. Cellular immune responses to ovalbumin and house dust mite in egg-allergic children. Allergy 2002; 57: 207−14.
- 4 Smart JM, Kemp AS. Increased Th1 and Th2 allergen-induced cytokine responses in children with atopic disease. Clin. Exp. Allergy 2002; 32: 796−802.
- 5 Kimura M, Yamaide A, Tsuruta S, Okafuji I, Yoshida T. Development of the capacity of peripheral blood mononuclear cells to produce IL-4, IL-5 and IFN-gamma upon stimulation with house dust mite in children with atopic dermatitis. Int. Arch. Allergy Immunol. 2002; 127: 191−7.
- 6 Kuperman DA, Huang X, Koth LL et al. Direct effects of interleukin-13 on epithelial cells cause airway hyperreactivity and mucus overproduction in asthma. Nat. Med. 2002; 8: 885−9.
- 7 Wills-Karp M, Luyimbazi J, Xu X et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282: 2258−61.
- 8 Grunig G, Warnock M, Wakil AE et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282: 2261−3.
- 9 Temann UA, Ray P, Flavell RA. Pulmonary overexpression of IL-9 induces Th2 cytokine expression, leading to immune pathology. J. Clin. Invest. 2002; 109: 29−39.
- 10 Kumar RK, Herbert C, Yang M, Koskinen AM, McKenzie AN, Foster PS. Role of interleukin-13 in eosinophil accumulation and airway remodelling in a mouse model of chronic asthma. Clin. Exp. Allergy 2002; 32: 1104−11.
- 11 O'Hehir R, Bal VQ, Uint D et al. An in vitro model of allergen dependent IgE synthesis by human B cells: comparison of the response of an atopic and non atopic individuals to Dermatophagoides spp. Immunology 1989; 64: 627−31.
- 12 Byron K, O'Brien R, Vaigos G, Wooton A. Dermatophagoides pteronyssinus ii-induced interleukin-4 and interferon-γ expression by freshly isolated lymphocytes of atopic individuals. Clin. Exp. Allergy 1994; 24: 878−83.
- 13 Imada M, Simons FE, Jay FT, Hayglass KT. Allergen-stimulated interleukin-4 and interferon-gamma production in primary culture: responses of subjects with allergic rhinitis and normal controls. Immunology 1995; 85: 373−80.
- 14 Gabrielsson S, Paulie S, Roquet A et al. Increased allergen-specific Th2 responses in vitro in atopic subjects receiving subclinical allergen challenge. Allergy 1997; 52: 860−5.
- 15 Kimura M, Tsuruta S, Yoshida T. IL-4 production by PBMC on stimulation with mite allergen is correlated with the level of serum IgE antibody against mite in children with bronchial asthma. J. Allergy Clin. Immunol. 2000; 105: 327−32.
- 16 Chang JH, Chan H, Quirce S et al. In vitro T-lymphocyte response and house dust mite-induced bronchoconstriction. J. Allergy Clin. Immunol. 1996; 98: 922−31.
- 17 Till S, Dickason R, Huston D et al. IL-5 secretion by allergen-stimulated CD4+ T cells in primary culture: relationship to expression of allergic disease. J. Allergy Clin. Immunol. 1997; 99: 563−9.
- 18 Li Y, Simons FE, HayGlass KT. Environmental antigen-induced IL-13 responses are elevated among subjects with allergic rhinitis, are independent of IL-4, and are inhibited by endogenous IFN-gamma synthesis. J. Immunol. 1998; 161: 7007−14.
- 19 Macaubas C, Prescott S, Smallacombe T et al. Perinatal and early childhood cytokine responses to environmental allergens. In: C Sanderson, ed. IL-5: from Molecule to Drug Target. Marcel Dekker Inc., New York, 1999, 119−26.
- 20 Jenmalm MC, Van Snick J, Cormont F, Salman B. Allergen-induced Th1 and Th2 cytokine secretion in relation to specific allergen sensitization and atopic symptoms in children. Clin. Exp. Allergy 2001; 31: 1528−35.
- 21 Tomita K, Lim S, Hanazawa T et al. Attenuated production of intracellular IL-10 and IL-12 in monocytes from patients with severe asthma. Clin. Immunol. 2002; 102: 258−66.
- 22 Smart JM, Horak E, Kemp AS, Robertson CF, Tang ML. Polyclonal and allergen-induced cytokine responses in adults with asthma. resolution of asthma is associated with normalization of IFN- gamma responses. J. Allergy Clin. Immunol. 2002; 110: 450−6.
- 23 Lee YC, Lee KH, Lee HB, Rhee YK. Serum levels of interleukins (IL) -4, IL-5, IL-13, and interferon-gamma in acute asthma. J. Asthma 2001; 38: 665−71.
- 24 Arima K, Umeshita-Suyama R, Sakata Y et al. Upregulation of IL-13 concentration in vivo by the IL13 variant associated with bronchial asthma. J. Allergy Clin. Immunol. 2002; 109: 980−7.
- 25 Holgate ST, Davies DE, Lackie PM, Wilson SJ, Puddicombe SM, Lordan JL. Epithelial−mesenchymal interactions in the pathogenesis of asthma. J. Allergy Clin. Immunol. 2000; 105: 193−204.
- 26 Venkayya R, Lam M, Willkom M, Grunig G, Corry DB, Erle DJ. The Th2 lymphocyte products IL-4 and IL-13 rapidly induce airway hyperresponsiveness through direct effects on resident airway cells. Am. J. Respir. Cell Mol. Biol. 2002; 26: 202−8.
- 27 Wenzel SE, Trudeau JB, Barnes S et al. TGF-beta and IL-13 synergistically increase eotaxin-1 production in human airway fibroblasts. J. Immunol. 2002; 169: 4613−9.
- 28 Ahdieh M, Vandenbos T, Youakim A. Lung epithelial barrier function and wound healing are decreased by IL-4 and IL-13 and enhanced by IFN-gamma. Am. J. Physiol. Cell Physiol. 2001; 281: C2029−38.
- 29 Zuany-Amorim C, Sawicka E, Manlius C et al. Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat. Med. 2002; 8: 625−9.
- 30 Wills-Karp M, Santeliz J, Karp CL. The germless theory of allergic disease: revisiting the hygiene hypothesis. Nat. Rev. Immunol. 2001; 1: 69−75.
- 31 Sudo N, Sawamura S, Tanaka K, Aiba Y, Kubo C, Koga Y. The requirement of intestinal bacterial flora for the development of an IgE production system fully susceptible to oral tolerance induction. J. Immunol. 1997; 159: 1739−45.
- 32 Shevach EM. Certified professionals: CD4 (+) CD25 (+) suppressor T cells. J. Exp. Med. 2001; 193: F41−6.
- 33 Koulis A, Robinson DS. The anti-inflammatory effects of interleukin-10 in allergic disease. Clin. Exp. Allergy 2000; 30: 747−50.
- 34 Umetsu DT, DeKruyff RH. Interleukin-10: The missing link in asthma regulation? Am. J. Respir. Cell Mol. Biol. 1999; 21: 562−3.
- 35 Corne JM, Lau L, Scott SJ, Davies R, Johnston SL, Howarth PH. The relationship between atopic status and IL-10 nasal lavage levels in the acute and persistent inflammatory response to upper respiratory tract infection. Am. J. Respir. Crit. Care Med. 2001; 163: 1101−7.
- 36 Gentile DA, Patel A, Ollila C et al. Diminished IL-10 production in subjects with allergy after infection with influenza A virus. J. Allergy Clin. Immunol. 1999; 103: 1045−8.
- 37 Seneviratne SL, Jones L, King AS et al. Allergen-specific CD8 (+) T cells and atopic disease. J. Clin. Invest. 2002; 110: 1283−91.
- 38 Grunig G, Corry DB, Leach MW, Seymour BW, Kurup VP, Rennick DM. Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. J. Exp. Med. 1997; 185: 1089−99.
- 39 Makela MJ, Kanehiro A, Borish L et al. IL-10 is necessary for the expression of airway hyperresponsiveness but not pulmonary inflammation after allergic sensitization. Proc. Natl Acad. Sci. USA 2000; 97: 6007−12.
- 40 Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W. Interleukin-10-deficient mice develop chronic enterocolitis. Cell 1993; 75: 263−74.
- 41 Borish L. IL-10: evolving concepts. J. Allergy Clin. Immunol. 1998; 101: 293−7.
- 42 Robinson DS, Tsicopoulos A, Meng Q, Durham S, Kay AB, Hamid Q. Increased interleukin-10 messenger RNA in atopic allergy and asthma. Am. J. Respir. Cell Mol. Biol. 1996; 14: 113−7.
- 43 Lamblin C, Desreumaux P, Colombel JF, Tonnel AB, Wallaert B. Overexpression of IL-10 mRNA in gut mucosa of patients with allergic asthma. J. Allergy Clin. Immunol. 2001; 107: 739−41.
- 44 John M, Lim S, Seybold J et al. Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. Am. J. Respir. Crit. Care Med. 1998; 157: 256−62.
- 45 Hobbs K, Negri J, Klinnert M, Rosenwasser LJ, Borish L. Interleukin-10 and transforming growth factor-beta promoter polymorphisms in allergies and asthma. Am. J. Respir. Crit. Care Med. 1998; 158: 1958−62.
- 46 Prescott S, Macaubas C, Holt B et al. Transplacental priming of the human immune system to environmental allergens: universal skewing of initial T-cell responses towards Th-2 cytokine profile. J. Immunol. 1998; 160: 4730−7.
- 47 Prescott S, Macaubas C, Smallacombe T et al. Development of allergen-specific T-cell memory in atopic and normal children. Lancet 1999; 353: 196−200.
- 48 Tang MLK, Kemp AS, Thorburn J, Hill D. Reduced interferon gamma secretion in neonates and subsequent atopy. Lancet 1994; 344: 983−5.
- 49 Spinozzi F, Agea E, Russano A et al. CD4+ IL13+ T lymphocytes at birth and the development of wheezing and/or asthma during the 1st year of life. Int. Arch. Allergy Immunol. 2001; 124: 497−501.
- 50 Kopp MV, Zehle C, Pichler J et al. Allergen-specific T cell reactivity in cord blood: the influence of maternal cytokine production. Clin. Exp. Allergy 2001; 31: 1536−43.
- 51 Ohshima Y, Yasutomi M, Omata N et al. Dysregulation of IL-13 production by cord blood CD4+ T cells is associated with the subsequent development of atopic disease in infants. Pediatr. Res. 2002; 51: 195−200.
- 52 Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J. Exp. Med. 1993; 178: 2123−30.
- 53 Jutel M, Pichler WJ, Skrbic D, Urwyler A, Dahinden C, Muller UR. Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J. Immunol. 1995; 154: 4187−94.
- 54 McHugh SM, Deighton J, Stewart AG, Lachmann PJ, Ewan PW. Bee venom immunotherapy induces a shift in cytokine responses from a TH- 2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin. Exp. Allergy 1995; 25: 828−38.
- 55 Hamid QA, Schotman E, Jacobson MR, Walker SM, Durham SR. Increases in IL-12 messenger RNA+ cells accompany inhibition of allergen-induced late skin responses after successful grass pollen immunotherapy. J. Allergy Clin. Immunol. 1997; 99: 254−60.
- 56 Akdis CA, Blaser K. Mechanisms of allergen-specific immunotherapy. Allergy 2000; 55: 522−30.
- 57 Fahy JV. Reducing IgE levels as a strategy for the treatment of asthma. Clin. Exp. Allergy 2000; 30 (Suppl. 1): 16−21.
- 58 Fick RB, Fox JA, Jardieu PM. Immunotherapy approach to allergic disease. Immunopharmacology 2000; 48: 307−10.
- 59 Bryan S, O'Connor B, Matti S et al. Effects of recombinant interleukin-12 on eosinophils, airways hyper-responsiveness, and the late asthmatic reaction. Lancet 2000; 356: 2149−53.
- 60 Leckie M, Ten Brinke A, Khan J et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airways hyper-responsiveness, and the late asthmatic reaction. Lancet 2000; 356: 2144−8.
- 61 Spiegelberg HL, Tighe H, Roman M, Broide D, Raz E. Inhibition of IgE formation and allergic inflammation by allergen gene immunization and by CpG motif immunostimulatory oligodeoxynucleotides. Allergy 1998; 53: 93−7.
- 62 Hopfenspirger MT, Agrawal DK. Airway hyperresponsiveness, late allergic response, and eosinophilia are reversed with mycobacterial antigens in ovalbumin-presensitized mice. J. Immunol. 2002; 168: 2516−22.
- 63 Tsai JJ, Liu YH, Shen HD, Huang SH, Han SH. Prevention of Der p2-induced allergic airway inflammation by mycobacterium-bacillus Calmette-Guerin. J. Microbiol. Immunol. Infect. 2002; 35: 152−8.
- 64 Major T, Wohlleben G, Reibetanz B, Erb KJ. Application of heat killed Mycobacterium bovis-BCG into the lung inhibits the development of allergen-induced Th2 responses. Vaccine 2002; 20: 1532−40.
- 65 Yang X, Fan Y, Wang S et al. Mycobacterial infection inhibits established allergic inflammatory responses via alteration of cytokine production and vascular cell adhesion molecule-1 expression. Immunology 2002; 105: 336−43.
- 66 Cavallo GP, Elia M, Giordano D, Baldi C, Cammarota R. Decrease of specific and total IgE levels in allergic patients after BCG vaccination: preliminary report. Arch. Otolaryngol. Head Neck Surg. 2002; 128: 1058−60.
- 67 Ota MO, Vekemans J, Schlegel-Haueter SE et al. Influence of mycobacterium bovis bacillus Calmette-Guerin on antibody and cytokine responses to human neonatal vaccination. J. Immunol. 2002; 168: 919−25.
- 68 Barlan IB, Tukenmez F, Bahceciler NN, Basaran MM. The impact of in vivo Calmette-Guerin bacillus administration on in vitro IgE secretion in atopic children. J. Asthma 2002; 39: 239−46.
- 69 Arkwright PD, David TJ. Intradermal administration of a killed mycobacterium vaccae suspension (SRL 172) is associated with improvement in atopic dermatitis in children with moderate-to-severe disease. J. Allergy Clin. Immunol. 2001; 107: 531−4.
- 70 Choi IS, Koh YI. Therapeutic effects of BCG vaccination in adult asthmatic patients: a randomized, controlled trial. Ann. Allergy Asthma Immunol. 2002; 88: 584−91.
Citing Literature
